

CORPORATE EVENTS

MEMO # 07-276

DATE: 11/13/07

ACTION:

Abraxis BioScience, Inc. ("ABBI") has announced a plan of business separation whereby each existing ABBI share will be converted into one APP Pharmaceuticals, Inc. ("APPX") Common Share and .25 (New) Abraxis, Inc. ("ABII") Common Shares. The distribution is scheduled to become effective on **November 14, 2007**.

This corporate event will be coordinated with the Options Clearing Corporation.

CATEGORY:

Separation Adjustment

EQUITY SYMBOL:

ABBI (Abraxis BioScience, Inc.)

ONECHICAGO SYMBOL:

ABBI1C changes to ABBI2C
APPX1C and ABII1C will not be listed

CME FUTURES SYMBOL:

ABB will change to AB2

EFFECTIVE DATE:

Wednesday, November 14, 2007

MULTIPLIER:

100 (e.g., 1.00 equals \$100.00) is unchanged

NEW DELIVERABLE PER CONTRACT:

- 1) 100 APP Pharmaceuticals, Inc. ("APPX") Common Shares
- 2) 25 (New) Abraxis, Inc. ("ABII") Common Shares

APPLICABLE CONTRACT MONTHS:

November and December 2007; March and June 2008

SETTLEMENT PRICES AND POSITIONS:

Unchanged

UNDERLYING PRICE:

The underlying price for the ABBI2C Futures contract deliverable, expressed in term of current market value, would be calculated as follows:

$$\text{ABBI2C} = \text{APPX} + .25 (\text{ABII})$$

Please note that the valuation would apply only to the ABBI2C deliverable in terms of current market value of the deliverable securities. The resulting price would not be equivalent to the daily settlement price of a futures contract month, whose determination would include cost of money carrying charges, adjustment for dividends, and other factors.

NOTES:

The forecasted effect of the upcoming corporate event on each clearing firm's positions can be viewed in infopac in the Corporate Event Initial Forecast Report (ONE712), the Corporate Event Final Forecast Report (ONE713), and the Corporate Event Forecast Audit Report (CPDBU710).

The details after the corporate event has been applied can be viewed in the Corporate Event Activity Report (ONE711).

If you have any questions regarding the information provided in the document, please call CME Clearing Risk Management hotline at (312) 648-3888.